Compare IMUX & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMUX | EDAP |
|---|---|---|
| Founded | 2016 | 1979 |
| Country | United States | France |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.6M | 128.9M |
| IPO Year | 2013 | 1998 |
| Metric | IMUX | EDAP |
|---|---|---|
| Price | $9.52 | $3.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $36.00 | $10.00 |
| AVG Volume (30 Days) | ★ 2.4M | 23.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,527,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.63 |
| 52 Week Low | $0.51 | $1.21 |
| 52 Week High | $10.91 | $5.05 |
| Indicator | IMUX | EDAP |
|---|---|---|
| Relative Strength Index (RSI) | 84.25 | 38.26 |
| Support Level | $0.75 | $3.13 |
| Resistance Level | N/A | $3.44 |
| Average True Range (ATR) | 0.43 | 0.21 |
| MACD | 1.07 | 0.01 |
| Stochastic Oscillator | 86.08 | 22.41 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.